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Introduction: To study the incidence and characteristics of mediasti-
nal nodal metastases without N1 nodal metastases (skip N2 metastases)
in patients with resected pIII/A/N2 non-small cell lung cancer.
Methods: A total of 323 non-small cell lung cancer patients who
underwent radical surgical resection with a systematic mediastinal
nodal dissection in 4-year period (2000–2003) were retrospectively
reviewed. The 85 patients (26%) at stage IIIA/N2 (pN2) were
grouped according to their skip metastases status. Patient data were
statistically analyzed.
Results: Skip N2 metastases were found in 21 patients (25%)
without N1 nodal involvement. The postoperative survival for skip
N2 disease was almost the same as that for pN2 disease with N1
nodal involvement. The incidence of N2 metastases seemed to be
more frequent in adenocarcinoma patients (p  0.005), but skip N2
metastases were significantly higher (p  0.001) in squamous cell
carcinoma patients. Although skip metastases involved more often
upper mediastinal lymph nodes and one station level, the difference
was not found statistically significant (p 0.227). Complication rate
showed no difference between analyzed groups of patients.
Conclusions: Sample mediastinal lymphadenectomy may not be
appropriate in surgery for non-small cell lung cancer because
skip metastases were found in 25% of patients without N1 nodal
involvement.
Key Words: Non-small cell lung cancer, N2 disease, Skip medias-
tinal metastases, Surgery.
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Lung cancer is the leading cause of cancer deaths in menand women in most industrialized countries. Defining the
stage of the disease is a key for planning therapy, estimating
prognosis and comparison the results.1 The extent of lymph
node involvement in patients with non-small cell lung cancer
(NSCLC) is the most important prognostic factor and influ-
ences multimodality treatment.2,3
Radical (RO) surgical resection is the standard treat-
ment for patients with stage I, II and IIIA disease. Systematic
dissection of hilar and mediastinal lymph nodes performed at
thoracotomy is mandatory.4 The 5-year survival is a function
primarily of TNM status and the overall medical status of the
patient. Nodal involvement of the mediastinum decreases the
5-year survival rate 20%.5,6
The number and location of mediastinal nodal stations
with metastases have been suggested to be of great oncologic
significance.7,8 Skip mediastinal nodal metastases are defined
as N2 nodal metastases without any N1 nodal involve-
ment.9,10 The incidence of skip N2 metastases is 20% to 40%
of all N2 diseases, but the nature and clinical significance
remain unclear. In addition, recent studies have suggested
that patients with skip N2 metastases tend to have a better
prognosis than other pN2 patients.11,12
We therefore analyzed the incidence and characteristics
of mediastinal nodal metastases without N1 nodal involve-
ment in patients with resected pIIIA/N2 NSCLC.
PATIENTS AND METHODS
A total of 323 NSCLC patients who underwent RO
surgical resection with systematic mediastinal nodal dissec-
tion at University Surgical Hospital, Split, Croatia, in a 4-year
period (2000–2003) were retrospectively reviewed. The pa-
tients had tumors in clinical stages I to III A, including cN2
patients with single-station nodal metastases. Eighty-five pa-
tients (25%) with stage IIIA/N2 (pN2 tumors) were
grouped according to their nodal metastases status. No induc-
tion therapy was given to these patients before surgery.
Patient characteristics are shown in Table 1.
The patients were 65 (76.4%) men and 20 (23.6%)
women, ranging in age from 32 to 78 years (median  SD,
54  9.5 years). There were 49 (57%) adenocarcinomas, 26
(30%) squamous cell carcinomas, and 10 (12%) of other types of
NSCLC using the World Health Organization classification.
All the operations performed were RO surgical resec-
tion with systematic ipsilateral mediastinal lymphadenec-
tomy. The surgical procedures performed were lobectomy in
52 (61%) patients, bilobecotmy in eight (9.5%), and pneu-
monectomy in 25 (29.4%) patients. All the ipsilateral medi-
astinal tissue containing the lymph nodes was dissected and
removed within anatomic landmarks. The nodal stations were
separately labeled and examined histologically. The number
of involved lymph nodes and their stations and the status of
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the nodal capsule were documented according to the recom-
mendations by Naruke et al.4 modified by the Bronchogenic
Carcinoma Cooperative Group of the Spanish Society of
Pneumology and Thoracic Surgery.9
Histopathologic evaluations were done by both macro-
scopic and microscopic examinations of several sections of
each node in 3- to 5-mm slices. Immunohistochemistry was
used to detect possible micrometastases in the cases of
microscopically negative N2 lymph nodes. Minimal N2 dis-
ease was defined as single-station lymph node involvement
with microscopic disease. Those patients received cisplatin-
and gemcitabine-based adjuvant chemotherapy. Patients with
proven two or more station N2 disease received adjuvant
concomitant chemoradiation therapy according the hospital
medical policy. No postoperative treatment was performed
for eight (9.5%) patients.
Skip N2 metastases were defined as N2 lymph node
metastases without any N1 node involvement. N2 lymph
nodes skip metastases to the highest mediastinal nodes with-
out any other N2 nodal involvement in patients with N1 nodal
metastases were determined not to be skip N2 metastases.13,14
Regarding the fact that one third of our patients reached
the estimated 5-year survival and the other two thirds reached
the estimated 3-year survival, our statistical analysis used
only the 3-year survival rate. Statistical analysis was per-
formed using Student’s t test (otherwise the Wilcoxon rank-
sum test) and the Fisher exact test when needed. All statistical
manipulations were performed using the SPSS for Windows
software system. Survival and patterns of failure were esti-
mated using the Kaplan-Meier method.
RESULTS
Patients at stage pIIIA (pN2) were the group to be
studied. It consisted of 85 (26%) patients who underwent RO
surgical resection and systematic mediastinal lymphadenec-
tomy. Skip N2 metastases (pN2/S) were found in 21 (25%)
patients operated on without any N1 nodal involvement
(Table 2.). There were 13 (62%) men and eight (38%) women
among them, which is a statistically significant gender distri-
bution difference compared with our overall NSCLC popu-
lation (p  0.05). Gender distribution in IIIA/N2 and IIIA/
skipN2 populations showed no statistically significant dif-
ference. Six (29%) patients with pN2/S were underwent
pneumonectomies and 15 (71%) underwent lobectomies; no
bilobectomies were performed. The primary lesion was right
TABLE 2. Comparison of IIIA/N2 and Skip IIIA/N2 Groups
IIIA/N2
No. (%)
Skip IIIA/N2
No. (%)
Overall rate 85 (26) 21 (25)
Gender
Male 65 (76) 13 (62)
Female 20 (24) 8 (38)
Histology
Adenocarcinoma 49 (57) 9 (18)
Squamous cell carcinoma 26 (30) 12 (46)
Other 10 (13) 0 (0)
Resection type
Lobectomy 52 (61) 15 (71)
Bilobectomy 8 (10) 0 (0)
Pneumonectomy 25 (29) 6 (29)
Tumor localization
Right 49 (58) 13 (62)
Left 36 (42) 8 (38)
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FIGURE 1. Columns represent percent of each histologic
non-small cell lung cancer subtype within total IIIA/N2 stage
population. Each column has two different parts, depending
on skip metastases presence. Note that skip N2 subgroup
represents almost 50% of N2 squamous cell lung cancer
population. Adenoca, adenocarcinoma.
TABLE 1. Overall Patient Characteristics
Characteristic No. (%)
Age, yr
55 150 (46.4)
55 173 (53.6)
Gender
Male 194 (60.0)
Female 129 (40.0)
Smoking history
20 pack-yr 117 (36.2)
30 pack-yr 206 (63.8)
Histology
Adenocarcinoma 203 (62.8)
Squamous cell carcinoma 96 (29.7)
Other 24 (7.5)
pT status
1 143 (44.3)
2 147 (45.5)
3 33 (10.2)
pN status
0 201 (62.2)
1 37 (11.5)
2 85 (26.3)
Pathologic status
IA 104 (32.2)
IB 79 (24.5)
IIA 17 (5.3)
IIB 38 (11.8)
IIIA 85 (26.3)
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sided in 13 (62%) patients and left sided in eight (38%)
patients.
The incidence of N2 metastases seemed to be more
frequent in adenocarcinoma patients (p 0.005), but skip N2
metastases were significantly higher (p 0.001) in squamous
cell carcinoma patients (Figure 1).
Although skip N2 metastases involved more often up-
per mediastinal lymph nodes and one station level, the dif-
ference was not found statistically significant (p  0.227)
(Tables 3 and 4.). It should be noted that regardless of
primary tumor location, distribution of skip metastases is
almost equal among the different mediastinal lymph nodes
stations (Table 4).
Complications rate showed no differences between an-
alyzed groups of patients. A 5-year survival rate analysis was
planned and was reached by one third of patients because the
other two thirds survived to 3-year follow-up (Figure 2).
Survival analysis regarding different IIIA/N2 subgroups
showed a statistically insignificant better prognosis of one
level IIIA/skip N2 subgroup (Figure 3).
DISCUSSION
Systematic nodal dissection is recommended after RO
surgical resection for NSCLC.2,4 Mediastinal nodal involve-
ment is the single most important factor for estimating prog-
nosis and indicating adjuvant therapy.15,16 The incidence of
recorded skip metastases in N2 group (25%) is similar to
some rates previously reported. Right-sided skip N2 metas-
tases are more often described by authors, which of which
was proven in our study.5
A higher incidence of skip N2 was revealed in squa-
mous cell carcinoma patients despite the fact that overall
nodal involvement was greater in adenocarcinoma patients.
These results indicate that the common mode of nodal spread-
ing in adenocarcinoma is continuous along lymphatic drain-
age pathways. A lower incidence of skip N2 in female
patients could be explained by higher incidence of adenocar-
cinoma in females. In addition, the unique anatomic and
genetic characteristics of each patient might contribute to skip
metastases development.17,18
Recent studies have suggested that patients with skip
N2 tend to have a better prognosis than other pN2
patients.6,9,18 Their survival rate almost reached that of
pN0 patients. A better prognosis of patients with skip N2
may be attributed to smaller number of positive lymph
nodes or to subpleural lymphatic drainage directly to the
mediastinum.2,17
Skip N2 involved more often upper mediastinal lymph
nodes and one station level. This is also connected with better
prognosis and survival as expected. Our data showed no
statistically significant changes in the survival rate in our
patients. This should be attributed to postoperative adjuvant
therapy, but the cost-benefit analysis of these data remains
unclear for the time being. A high percentage of one station
level nodal involvement and histologic tumor differentiation
favor survival in some patients with skip N2.
TABLE 3. Non-small Cell Lung Cancer Site and Skip Metastases Appearance
Mediastinal Lymph Node Stations
HM UP PAR LP SA PA SC PE PL
Tumor site
Upper right lobe 2 1 1 1 0 2 1 1 0
Middle right lobe 1 0 0 0 0 0 0 0 0
Lower right 1 1 1 1 1 1 0 0 1
Upper left lobe 1 1 1 1 1 0 1 1 1
Lower left 0 0 1 1 1 1 1 1 2
Total: 33 5 3 4 4 3 4 3 3 4
Regardless of primary tumor location, skip metastases distribution is well balanced, with no lobe-specific spreading pattern.
HM, highest mediastinal; UP, upper paratracheal; PAR, paratracheal; LP, lower paratracheal; SA, subaortic; PA, para-aortic; SC,
subcarinal; PE, paraesophageal; PL, pulmonary ligament.
TABLE 4. Skip Metastases: Multilevel and One-Level
Mediastinal Lymph Node Involvement
No. (%) of Patients
Multilevel involvement 11 (52)
Three stations 1
Two stations 10
One-level involvement 10 (48)
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FIGURE 2. Five-year survival rates after surgery according
to N status. The fourth and the fifth years of follow-up refer
only to one third of the patients because the other two
thirds survived to 3-year follow-up. Differences in survival
rates for N0, N1, and N2 groups are statistically significant
(p  0.05).
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Nowdays, neither computed tomography nor positron
emission tomography could be accurate in preoperative stag-
ing of each positive lymph node. Videomediastinoscopy and
video-assisted thoracic surgery should be of great help in
defining preoperative clinical staging and modifying treat-
ment options in NSCLC.
In our opinion, systematic nodal dissection should be
mandatory part of RO surgical strategy for NSCLC. Selected
lymph node biopsy and lobe-specific lymph node dissection
are not accurate for exact mediastinal staging.2,5 Radical and
extended lymph node dissection puts some patients at risk by
unnecessarily prolonging operating time, and information
gathered by these methods does not provide the patients any
survival benefit.8
Finally, we can say that due to the presence of skip
metastases, systematic nodal dissection should be performed in
all cases as it is the only way to guarantee accurate nodal staging.
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FIGURE 3. Five years after surgery, the survival of the dif-
ferent pN2 subgroups is shown. Although one-level skip
pN2 is a subgroup of the N2 group with a better progno-
sis, differences in survival rates for one-level skip N2, multi-
level skip N2, and N2 (N1) groups are not statistically
significant (p  0.05).
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